Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Seven Consecutive Weeks of Increase! US 30-Year Mortgage Rate Surges to 7.49%, Hitting a Nearly Three-Year High

Seven Consecutive Weeks of Increase! US 30-Year Mortgage Rate Surges to 7.49%, Hitting a Nearly Three-Year High

智通财经智通财经2026/10/07 13:46
Show original

The 30-year US mortgage rate has risen for seven consecutive weeks to 7.49%, reaching a nearly three-year high; the conflict in Iran has pushed up US Treasury yields, and home purchase applications have fallen to their lowest level in a year.

According to Zhihu Finance APP, mortgage rates in the United States have risen for the seventh consecutive week, reaching their highest level in nearly three years and further aggravating the country's housing affordability issues.

Data released by the Mortgage Bankers Association (MBA) on Wednesday showed that for the week ending October 2, the 30-year fixed mortgage rate rose by 19 basis points to 7.49%, the highest point since November 2023. Over the past three weeks, this rate has climbed about 0.5 percentage points in total, marking the fastest increase since early 2023.

Seven Consecutive Weeks of Increase! US 30-Year Mortgage Rate Surges to 7.49%, Hitting a Nearly Three-Year High image 0

Since the outbreak of the Iran war, rising energy costs and overall inflation have continued to push up the yield on 10-year U.S. Treasury bonds, which has a significant impact on mortgage rates. On Monday, the 10-year yield reached its highest level since 2002. Coupled with persistently high housing prices, increased mortgage rates have also dampened the momentum of both existing and new home sales.

The MBA Purchase Index, which measures mortgage application volume, fell 2.1%, sliding to its lowest level in more than a year. The MBA Refinance Index dropped 7.5%, extending the downward trend that began in mid-August.

The MBA survey has been conducted weekly since 1990, with samples collected from mortgage bankers, commercial banks, and savings institutions, covering more than 75% of all U.S. retail residential mortgage applications.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

VIP Play extends maturity on 12% convertible notes held by Hackel, Access Fund I LP

Vip Play amended convertible note purchase agreements with Rick Hackel, The Access Fund I, LP, extending maturity dates. Hackel notes totaling $300,000 now mature Feb. 28, 2027; Access note of $150,000 now matures Aug. 31, 2027. Notes carry 12% annual interest; principal and accrued interest due in a single balloon payment unless converted to common stock. Changes take effect Sept. 1, 2026; amendments or waivers now require only the company and the relevant noteholder. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vip Play Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046094), on October 07, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/07 14:28

MTY Food Group Faces Near-Term Headwinds Ahead of 3Q Results -- Market Talk

1019 ET - MTY Food Group faces persistent macroeconomic headwinds and high uncertainty driven by intense quick-service restaurant competition. RBC's Ryland Conrad says in a report that uncertainty hinges around the scope, probability, timing and valuation of any potential transaction around MTY's ongoing strategic review, now in its tenth month. While an outcome could act as a catalyst for the stock, "sustained macro and competitive headwinds to limit any meaningful improvement in the near term." As a result, Conrad says the "focus remains on MTY's organic growth trajectory" where management continues improving and strengthening its network. The company is expected to report its 3Q results on Oct. 9. (adriano.marchese@wsj.com) (END) Dow Jones Newswires October 07, 2026 10:19 ET (14:19 GMT)

Dow Jones•2026/10/07 14:19

BUZZ - Worthington Steel shares fall as quarterly profits miss expectations

October 7 - Worthington Steel (WS.N) shares fell 8.8%, closing at $24.93. WS reported (link) adjusted earnings per share of $0.57 for the first quarter, below analysts’ expectations of $0.68, according to data compiled by LSEG. The company reported quarterly revenue of $953.9 million, exceeding analysts’ estimates of $885.9 million, mainly due to the acquisition of Kloeckner. The company stated that the sale of Kloeckner Disposal Group is expected to be completed within one year after the acquisition. Of the two brokerages covering the stock, one rates it “Buy” and the other “Hold”; the median price target is $46. Including the day’s movement, WS shares are up 1.4% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translations may contain errors or fail to capture the intended context; Reuters does not guarantee their accuracy and provides them purely for reader convenience. Reuters assumes no liability for any loss or damage arising from the use of these automated translation features.)

路透社•2026/10/07 14:16

BUZZ-Ultragenyx profits from selling a U.S. FDA voucher worth $210 millions

October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87 ** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash ** The company received the voucher after FDA approval of its drug Genglycos (link) for treating Glycogen Storage Disease Type Ia (also known as von Gierke disease) ** According to the licensing agreement, upon completion of the transaction, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health ** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet replied ** The recommended retail price per patient for Genglycos in the U.S. is $2.7 million ** As of the previous trading day’s close, the stock had fallen about 35% year to date (In order to facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be erroneous or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation tools.)

路透社•2026/10/07 14:16